COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: An instrumental variable analysis

Epidemiology

Volumn 24, Issue 3, 2013, Pages 352-362

  Davies, Neil M ^a   Smith, George Davey ^a   Windmeijer, Frank ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ADULT; AGED; ARTICLE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; UPPER GASTROINTESTINAL TRACT;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 84876289716     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e318289e024     Document Type: Article

References (66)

1. Chen Y, Briesacher BA. Use of instrumental variable in prescription drug research with observational data: a systematic review. J Clin Epidemiol. 2011;64:687-700.
2. Angrist JD, Imbens G W, Rubin DB. identifcation of causal effects using instrumental variables. J Am Stat Assoc. 1996;91:444-455.
3. Angrist JD, Lavy V. Using Maimonides' rule to estimate the effect of class size on scholastic achievement. Quarterly J Econ. 1999;114:533-575.
4. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064-1070.
5. Timpson NJ, Lawlor DA, Harbord RM, et al. c-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet. 2005;366:1954-1959.
6. Davey Smith G, Ebrahim S. What can Mendelian randomisation tell us about modifable behavioural and environmental exposures? BMJ. 2005;330:1076-1079.
7. Klungel OH, Martens e P, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004;57:1223-1231.
8. Martense P, Pestman WR, De Boer A, Belitser S V, Klungel OH. instrumental variables: application and limitations Epidemiology. 2006; 17: 260-267.
9. Angrist JD. estimation of limited dependent variable models with dummy endogenous regressors. J Bus Econ Stat. 2001;19:2-28.
10. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. evaluating short-term drug effects using a physician-specifc prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275.
11. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefts and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinfammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006;54:3390-3398.
12. Rassen JA, Schneeweiss S, Glynn RJ, Mittleman MA, Brookhart MA. instrumental variable analysis for estimation of treatment effects with di-chotomous outcomes. Am J Epidemiol. 2009;169:273-284.
13. Schneeweiss S, Seeger JD, Landon J, Walker AM. aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358:771-783.
14. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. a Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of frst-time prescriptions for cOX-2 inhibitors. J Clin Epidemiol. 2005;58:98-102.
15. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31:561-572.
16. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. instrumental variables i: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62:1226-1232.
17. Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schnee-weiss S. evaluating the validity of an instrumental variable study of neu-roleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care. 2007;45(10 suppl 2):S116-S122.
18. Brookhart MA, Rassen JA, Schneeweiss S. instrumental variable methods in comparative safety and effectiveness research. Pharmacoepide-miol Drug Saf. 2010;19:537-554.
19. Wang PS, Schneeweiss S, Avorn J, et al. risk of death in elderly users of conventional VS. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
20. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. risk of death associated with the use of conventional versus atypical antipsy-chotic drugs among elderly patients. CMAJ. 2007;176:627-632.
21. Hernán MA, Wilcox AJ. epidemiology, data sharing, and the challenge of scientifc replication. Epidemiology. 2009;20:167-168.
22. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. instrumental variables ii: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009;62:1233-1241.
23. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-2029.
24. Silverstein F, Faich G, Goldstein J, et al. gastrointestinal toxicity with celecoxib vs nonsteroidal anti-infammatory drugs for osteoarthritis and rheumatoid arthritis: the claSS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
25. Bombardier C, Laine L, Reicin A, et al. comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343:1520-1528.
26. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat. 2007;3:article 14
27. Anon. gPrD. the database. 2010. www.gprd.com/products/database.asp.
28. accessed 20 October 2010, Available at: http://www.gprd.com/home/home. asp. accessed 20 October 2010.
29. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general Practice research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4-14
30. Khan n F, Harrison SE, Rose P W. Validity of diagnostic coding within the general Practice research Database: a systematic review. Br J Gen Pract. 2010;60:e128-e136.
31. Wheeler B W, Metcalfe C, Gunnell D, Stephens P, Martin RM. Population impact of regulatory activity restricting prescribing of cOX-2 inhibitors: ecological study. Br J Clin Pharmacol. 2009;68:752-764.
32. Dieppe PA, Ebrahim S, Martin RM, Jüni P. lessons from the withdrawal of rofecoxib. BMJ. 2004;329:867-868.
33. Margulis AV, García rodríguez LA, Hernández- Díaz S. Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 2009;18:900-909.
34. Hernán MA, Robins JM. instruments for causal inference: an epidemiologist's dream? Epidemiology. 2006;17:360-372.
35. Abrahamowicz M, Beauchamp ME, Ionescuittu R, Delaney JA, Pilote L. reducing the variance of the prescribing preference-based instrumental variable estimates of the treatment effect. Am J Epidemiol. 2011;174:494-502.
36. Trelle S, Reichenbach S, Wandel S, et al. cardiovascular safety of non-steroidal anti-infammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
37. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817-838.
38. Clarke PS, Windmeijer F. instrumental variable estimators for binary outcomes. The Centre for Market and Public Organisation Working Papers. 2010;239.
39. Clarke PS, Windmeijer F. identifcation of causal effects on binary outcomes using structural mean models. Biostatistics. 2010;11:756-770.
40. Wooldridge J. Econometric Analysis of Cross Section and Panel Data. cambridge, Ma: Mit Press; 2002.
41. Greene W. Econometric Analysis. Upper Saddle river, nJ: Prentice Hall; 2002.
42. Hansen L P. large sample properties of generalized method of moments estimators. Econometrica. 1982;50:1029-1054.
43. Balke A, Pearl J. Bounds on treatment effects from studies with imperfect compliance. J Am Stat Assoc. 1997;92:1171-1176.
44. Palmer T, Ramsahai R, Didelez V, Sheehan N. Nonparametric bounds for the causal effect in a binary instrumental variable model. Stata J. 2011;3:345-367.
45. Angrist JD, Imbens G W. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assoc. 1995;90:431-442.
46. Dawid A P. causal inference without counterfactuals. J Am Stat Assoc. 2000;95:407-424.
47. Stock J, Yogo M. Testing for weak instruments in linear iV regression. National Bureau of Economic Research Technical Working Paper Series. 2002;no. 284. available at: http://www.nber.org/papers/t0284.pdf. accessed 1 april 2010.
48. Efron B. Better bootstrap confdence intervals. J Am Stat Assoc. 1987;82:171-185
49. Statacorp. Stata Statistical Software: release 12. college Station, tX: Statacorp lP; 2011.
50. Baum C F, Schaffer ME, Stillman S. ivreg2: Stata module for extended instrumental variables/2SlS, gMM and ac/Hac, liMl and k-class; 2010.
51. Van Staa T P, Leufkens HG, Zhang B, Smeeth L. a comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med. 2009;6:e1000194.
52. Hippisley-cox J, Coupland C, Logan R. risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-infammatory drugs: population based nested case-control analysis. BMJ. 2005;331:1310-1316.
53. Hippisley-cox J, Coupland C. risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-infammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.
54. De Torbal A, Boersma E, Kors JA, et al. incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the rotterdam Study. Eur Heart J. 2006;27:729-736.
55. Van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotec-tive coverage of nSaiD use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three european databases. Gut. 2011;60:1650-1659.
56. Van Staa T P, Smeeth L, Persson I, Parkinson J, Leufkens HG. What is the harm-beneft ratio of cox-2 inhibitors? Int J Epidemiol. 2008;37: 405-413.
57. McMahon AD. approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003;12:551-558.
58. Lalonde R. evaluating the econometric evaluations of training programs with experimental data. Am Econ Rev. 1986;76:604-620.
59. Lawlor DA, Davey Smith G, Ebrahim S. commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol. 2004;33:464-467.
60. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363:1724-1727.
61. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analy-sis of observational studies. BMJ. 1998;316:140-144
62. Weiss NS. the new world of data linkages in clinical epidemiology: are we being brave or foolhardy? Epidemiology. 2011;22:292-294.
63. Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. nonexperimen-tal comparative effectiveness research using linked healthcare databases. Epidemiology. 2011;22:298-301.
64. Davey Smith G, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
65. Hernán MA. With great data comes great responsibility: publishing comparative effectiveness research in epidemiology. Epidemiology. 2011;22:290-291.
66. Chandra A, Jena AB, Skinner JS. the pragmatist's guide to comparative effectiveness research. J Econ Perspect. 2011;25:27-46.